Navigation Links
Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
Date:1/23/2010

s that its common shares will be subject to delisting from the Nasdaq Global Market. If the Company receives a delisting notification, it may appeal to the Listing Qualifications Panel or apply to transfer its common shares to the Nasdaq Capital Market if Æterna Zentaris satisfies at such time all of the initial listing standards on the Nasdaq Capital Market, other than compliance with the minimum closing bid price requirement. If the application to the Nasdaq Capital Market is approved, then the Company will have an additional 180-day grace period in order to regain compliance with the minimum bid price requirement while listed on the Nasdaq Capital Market.

About Æterna Zentaris Inc.

Æterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. se
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 Cambridge ... solutions driven by Semantic Web technology, and ... information and services for the academic and scientific, ... its joint solution ‘Smart Data Lake for Clinical ... for the 2015 Bio-IT ‘Best of Show’ Award. ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... TORONTO , April 16, 2015 /PRNewswire/ - Portage ... PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce ... Investor Show on April 25, 2015 to be held ... Dr. Gregory Bailey and Mr. James ... overview and an update on the key programs at ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
Breaking Biology Technology:Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... a long-planned departure from its traditional focus, high-end computer ... U.S. Army for development of two different products. , ... it has secured $2.2 million in federal contracts for ... the Armys Research, Development and Engineering Command (CERDEC) to ...
... Inc. for the quarter ended March 31 rose to $142.5 ... company earned the same quarter of 2004. , ,Profit for ... even $150 million, compared to $78.3 million a year ago. ... more than $10 per share Tuesday and Wednesday from Monday's ...
... Milwaukee Merge eFilm , the Milwaukee-based ... Inc., continued to build momentum leading into its proposed ... net sales of just more than $10.5 million in ... first quarter 2004, after a 19 percent year-over-year jump ...
Cached Biology Technology:SLE of Eau Claire lands $2.2 million in federal contracts 2SLE of Eau Claire lands $2.2 million in federal contracts 3Merge eFilm earnings jump precedes planned merger 2Merge eFilm earnings jump precedes planned merger 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... controlled trial of fish oil given intravenously to patients ... exchange, reduces inflammatory chemicals and results in a shorter ... open access journal Critical Care investigated the ... solution for patients with sepsis, finding a significant series ...
... 1. Prescribed Opioids Associated with Significant Risk for ... oxycodone, have increased significantly over the past decade. As ... common, the deaths associated with opioids increase. Opioid overdose ... Researchers sought to determine the rate of opioid overdose ...
... MIT and Harvard Medical School have built targeted nanoparticles ... medicine, an advance that potentially provides an alternative to ... The particles, dubbed "nanoburrs" because they are coated with ... target proteins, can be designed to release their drug ...
Cached Biology News:Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 2Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 3New nanoparticles target cardiovascular disease 2
HOXC11 Antibody...
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
pH-insensitive fluorescence (pH 2-12)...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Biology Products: